Every intervention Outliyr has scored for cellular senescence, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for cellular senescence; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
42 of 100 evaluated interventions score 3.0+ out of 10 for cellular senescence · 6 comparisons
Direct mechanism: Zhu 2015 identified senescent-cell anti-apoptotic pathway vulnerabilities; Zhu 2017 identified fisetin as senolytic in selected cell types. The score stays bounded because Senolytics evidence for cellular senescence can depend on…
Harrison 2009 anchors the most relevant signal. Rapamycin fits cellular senescence when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints…
Kumar 2023 anchors the most relevant signal. Glycine fits cellular senescence because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Kiechl 2018 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Autophagy clears senescence-associated cellular damage in mechanistic and animal models, but no human senescence endpoint is…
Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points in the same direction, but route, dose, baseline status, and outcome…
Hamaya 2025 supports the strongest part of the claim. The existing rationale points to this narrower claim: Heat-shock protein signaling may support protein folding and resilience in aging tissues, but there are…
Red Light Therapy may improve mitochondrial function in stressed cells, but direct human senescence endpoints are missing. Hamblin 2017 supports inflammation and mitochondrial pathways that overlap with senescence biology. That is enough…
Metformin influences mTOR and AMPK pathways, which are linked to senomorphic activity, yet human trials measuring senescence markers remain sparse. The ongoing TAME trial aims to clarify whether Metformin can meaningfully alter…
Demidenko 2021 supports direction more than certainty. The existing rationale points to this narrower claim: Frailty reduction suggests downstream aging-biology relevance, but there is no direct human senescence-marker trial. Treat as mechanism-adjacent,…
Hachmo 2020 supports reductions in immunosenescent blood cells after sixty hard-chamber sessions in older adults. Replication and clinical-outcome linkage are missing. Score above neutral but below strong-recommend because the evidence ecosystem is…
High-Dose Melatonin earns a cautious cellular-senescence score because oxidative stress, mitochondrial signaling, and oncology-adjuvant findings overlap with aging biology. Posadzki's umbrella review still flagged methodological heterogeneity across melatonin health outcomes (Posadzki et…
The evidence points to a plausible use case without proving a universal response. Leung GKW et al. 2025 is the best anchor here because it reports 33 randomized trials and 2821 individuals…
Rodriguez 2016 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Cellular-senescence rationale is preclinical and mitochondrial. Human senescence-marker trials are not available, and this verified source…
Semaglutide may reduce senescence pressure indirectly through weight loss, glycemic control, and lower inflammatory signaling. Perkovic 2024 supports organ-risk improvement in a metabolically high-risk group, but it does not measure senescent-cell burden.…
Dasatinib plus quercetin reduced adipose and skin senescent-cell markers and SASP factors in 9 diabetic kidney disease patients within 11 days (Hickson 2019). Justice 2019 showed feasibility in IPF (n=14) with improved…
Wittholz 2024 reports Systematic review found heterogeneity high enough that planned meta-analysis was not possible. Hughes 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether…
No direct senescence data. Neurofeedback changes brain-state regulation and behavior; it does not have trials showing senescent-cell reduction or senescence-marker change. Keep this low and indirect, tied only to cognitive preservation and…
He 2024 reports aged-fibroblast and myofibroblast senescence mechanisms, and Pickart reviews discuss youthful gene-expression patterns. Human senescence-marker trials are missing.
Visceral fat reduction may lower senescence-associated inflammatory signaling indirectly; no direct senolytic activity is established.
Regular aerobic exercise may reduce senescence-associated inflammatory burden through metabolic and immune pathways. Direct human evidence that Zone 2 clears senescent cells is not strong enough for a higher score.
No direct human senescence-marker evidence. Mechanical loading may improve tissue function, but senescence-specific claims should stay exploratory.
Damaged mitochondria are associated with cellular aging, so the mitophagy mechanism is relevant. Direct human senescence-marker evidence is still insufficient.
Mitochondrial dysfunction drives senescence biology, but SS-31 has no direct human senescence-marker trial and should not be treated as a senolytic or proven senomorphic compound.
Bonanni et al. 2025 found favorable ex vivo marker shifts around oxidative stress, senescence, and differentiation in human myoblast work. This supports exploration, not a human senescence intervention.
Exercise may reduce senescence burden in some tissues through metabolic and inflammatory pathways. Exact 4x4 senescence evidence remains mechanistic and indirect.
Oxidative-stress reduction may reduce senescence pressure mechanistically. No direct human senescence-marker RCTs.
Telomerase activation and telomere effects point toward cellular-senescence relevance, but no human senescence-marker RCT exists. Khavinson 2003 and Al-dulaimi 2025 support cell-line mechanisms; they do not prove reduced p16, SASP, tissue aging,…
Cellular senescence was listed among the improved hallmarks in the older-adult RCT, but it is a mechanistic biomarker finding without independent replication.
Oxidative-stress reduction may ease senescence pressure mechanistically, but no human senescence-marker trial exists.
Mostly preclinical senescence-pathway signals; no human senescence-marker data.
NAD+ supports DNA repair and stress-response biology, but human senescence-marker trials are missing. The score reflects indirect rationale, not direct clearance of senescent cells.
Cellular-senescence claims are mostly preclinical. Resveratrol can modulate stress-response pathways in cells and animals, but human trials have not shown reliable senescent-cell burden reduction, p16INK4a change, or SASP-marker improvement. The SIRT1 story…
Some flavonoids (fisetin, quercetin) have senolytic interest, but that is a specific-member story scored elsewhere, not the dietary class.
Immune surveillance of senescent cells is a plausible pathway, but thymosin alpha-1 has no human senescence-marker trial. This remains a low-confidence healthspan extension angle.
Senescence signals are preclinical only. No human senescence marker, epigenetic clock, or tissue-aging trial supports berberine as a senolytic.
NAD+ supports DNA repair and senescence-linked pathways, but direct human cellular-senescence outcomes remain indirect.
Transcriptional-drift reversal is aging-relevant, but no dedicated senescence-marker endpoint has been studied for J-147.
Senescence is one of pine pollen's better preclinical signals. Mao 2012 reported delayed senescence in human diploid fibroblasts in vitro alongside restored antioxidant enzyme activity in D-galactose-aged mice, which is a direct…
TRT has theoretical links to aging biology but no practical human senescence outcome evidence. It should not be framed as a senolytic, geroprotector, or cellular-aging reset.
COX-2 contributes to inflammatory aging pathways and the senescence-associated secretory phenotype, but human senescence-marker trials do not justify celecoxib as a senolytic or longevity intervention.
5-Amino-1MQ reactivated senescent muscle stem cells in aged mice (Neelakantan 2019); no systemic senescence data in people.
The Cellular Fragility Syndrome framing is company-originated and has no independent diagnostic authority. Robinson 2024 (Robinson 2024) tested clinical biomarkers, not validated senescence markers such as p16INK4a, SASP cytokines, DNA-damage markers, or…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 14 of 42 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Senolytics | Not priced yet | ||
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Molecular Hydrogen | Not priced yet | ||
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| High-Dose Melatonin | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Essential Amino Acids | Not priced yet | ||
| Neurofeedback | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Urolithin A | $50–$100 | 500 mg/day | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Astaxanthin | Not priced yet | ||
| Epitalon | $95–$1,100 | 5-10 mg/day subcutaneous | Grey market |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| Ergothioneine | Not priced yet | ||
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| Resveratrol | Not priced yet | ||
| Polyphenols (Dietary) | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| J-147 | Not priced yet | ||
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Celebrex (Celecoxib) | Not priced yet | ||
| 5-Amino-1MQ | $95–$190 | 50 to 100 mg oral, once daily | Grey market |
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live endurance-cardio subrating, not by BioHarmony overall, and the order flips. SLU-PP-332 leads at 6.5–7.0/10 despite carrying the lowest overall score on the…
No. Omega-3 scores 6.5–7.0/10 and C15:0 3.0/10, and the evidence behind the two is not close. C15:0 has two small human trials. Omega-3 has outcome trials, prescription forms…
Different jobs, same shelf. Quercetin scores 6.5–7.0/10 and curcumin 5.5–6.0/10, and that gap is the liver-safety signal rather than a difference in effect. Curcumin wins joints, inflammatory markers,…
Buy the panel. Red light therapy scores 7.5–8.0/10 against HBOT's 5.5–6.0/10, costs $17 to $43 a month against $3,000 to $6,000, and does not lose a single use…
Metformin scores 6.5–7.0/10 and rapamycin 6.5–7.0/10, which settles nothing. Rapamycin owns the aging-biology rows: longevity 8.0/10, autophagy 8.5/10, senescence 7.8/10, plus replicated mouse lifespan data. Metformin owns everyday…
Urolithin A scores 6.5–7.0/10 and direct NAD+ scores 5.0–5.5/10, and the gap is about human evidence rather than biology. Urolithin A has completed human trials with measured mitochondrial…
Senolytics, at 8.0–8.5 out of 10 for cellular senescence. Direct mechanism: Zhu 2015 identified senescent-cell anti-apoptotic pathway vulnerabilities; Zhu 2017 identified fisetin as senolytic in selected cell types.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 6.5–7.0 out of 10 for cellular senescence.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for cellular senescence but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
42 of the 100 interventions evaluated for cellular senescence score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
